Dexmedetomidine and Delirium in Patients After Cardiac Surgery

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative delirium (POD) is a frequently occurring complication after cardiac surgery. Its occurrence is associated with worse outcomes of patients, including increased morbidity, prolonged hospital stay, increased medical cost, and higher mortality. It is also associated with long-term cognitive decline and decreased quality of life. However, until recently, pharmacological interventions that can effectively prevent its occurrence are still limited. The purpose of this study is to investigate whether perioperative dexmedetomidine use can decrease the incidence of postoperative delirium in patients undergoing cardiac surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

Patients of 60 years or older who are planning to receive cardiac surgery (CABG and/or valve replacement surgery)

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

1. Refuse to participate;

2. Preoperative history of schizophrenia, epilepsia, Parkinson syndrome, or severe dementia;

3. Inability to communicate in the preoperative period because of severe visual/auditory dysfunction or language barrier;

4. History of brain injury or neurosurgery;

5. Preoperative sick sinus syndrome, severe bradycardia (HR < 50 bpm), second-degree or above atrioventricular block without pacemaker;

6. Severe hepatic dysfunction (Child-Pugh class C);

7. Severe renal dysfunction (requirement of renal replacement therapy);

8. Other conditions that are considered unsuitable for participation.